Novavax, Inc. ( NVAX) Jefferies London Health Care Conference 2025 November 19, 2025 11:30 AM EST
Business Individuals
Ruxandra Draghia-Akli – Executive VP and Head of Research Study & & Advancement
James Kelly – Executive VP, CFO & & Treasurer
Teleconference Individuals
Jiale Tune – Jefferies LLC, Research Study Department
Discussion
Jiale Tune
Jefferies LLC, Research Study Department
Welcome to Jefferies London Health Care Conference 2025. My name is Roger Tune, among the senior experts cover semicap biotech in the U.S. It is my satisfaction to have my next fireside chat with Novavax. Welcome, Jim and Ruxa.
Ruxandra Draghia-Akli
Executive VP and Head of Research Study & & Advancement
Really great to be here.
James Kelly
Executive VP, CFO & & Treasurer
Thanks for having us once again this year.
Question-and-Answer Session
Jiale Tune
Jefferies LLC, Research Study Department
Definitely. Invite you. Okay. So Jim, if you can simply provide us a bit sort of a summary of the Novavax today. I believe it’s various from in 2015 for sure, and after that the huge tactical focus for the brand-new Novavax. And after that why do not you provide us a summary?
James Kelly
Executive VP, CFO & & Treasurer
Right. Wonderful. So thanks, everybody, for joining us today. For much of you, you might recognize with Novavax from our latest history throughout the pandemic. Among the really couple of business that split the code in fact developed an extremely effective COVID vaccine. And you might be asking yourself, how did this business attain that when a lot of huge pharma could not do it? And the response is our innovation. Our core innovation based upon subunit protein nano-based innovation for antigen development when integrated with what our company believe is the most efficient adjuvant Matrix-M.
And we believe that, that’s been crucial to our success that you will see in the type of both our COVID vaccine
Source: Seeking Alpha.
